Applications of CRISPR systems in respiratory health: Entering a new 'red pen' era in genome editing

Colette Moses, Parwinder Kaur

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Respiratory diseases, such as influenza infection, acute tracheal bronchitis, pneumonia, tuberculosis, chronic obstructive pulmonary disease, asthma, lung cancer and nasopharyngeal carcinoma, continue to significantly impact human health. Diseases of the lung and respiratory tract are influenced by environmental conditions and socio-economic factors; however, many of these serious respiratory disorders are also rooted in genetic or epigenetic causes. Clustered regularly interspaced palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins, isolated from the immune system of prokaryotes, provide a tool to manipulate gene sequences and gene expression with significant implications for respiratory research. CRISPR/Cas systems allow preclinical modelling of causal factors involved in many respiratory diseases, providing new insights into their underlying mechanisms. CRISPR can also be used to screen for genes involved in respiratory processes, development and pathology, identifying novel disease drivers or drug targets. Finally, CRISPR/Cas systems can potentially correct genetic mutations and edit epigenetic marks that contribute to respiratory disorders, providing a form of personalized medicine that could be used in conjunction with other technologies such as stem cell reprogramming and transplantation. CRISPR gene editing is a young field of research, and concerns regarding its specificity, as well as the need for efficient and safe delivery methods, need to be addressed further. However, CRISPR/Cas systems represent a significant step forward for research and therapy in respiratory health, and it is likely we will see the breakthroughs generated from this technology continue.

Original languageEnglish
Pages (from-to)628-637
Number of pages10
JournalRespirology
Volume24
Issue number7
DOIs
Publication statusPublished - Jul 2019

Cite this

@article{254ad37b3f32420d83a8699fccb145f5,
title = "Applications of CRISPR systems in respiratory health: Entering a new 'red pen' era in genome editing",
abstract = "Respiratory diseases, such as influenza infection, acute tracheal bronchitis, pneumonia, tuberculosis, chronic obstructive pulmonary disease, asthma, lung cancer and nasopharyngeal carcinoma, continue to significantly impact human health. Diseases of the lung and respiratory tract are influenced by environmental conditions and socio-economic factors; however, many of these serious respiratory disorders are also rooted in genetic or epigenetic causes. Clustered regularly interspaced palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins, isolated from the immune system of prokaryotes, provide a tool to manipulate gene sequences and gene expression with significant implications for respiratory research. CRISPR/Cas systems allow preclinical modelling of causal factors involved in many respiratory diseases, providing new insights into their underlying mechanisms. CRISPR can also be used to screen for genes involved in respiratory processes, development and pathology, identifying novel disease drivers or drug targets. Finally, CRISPR/Cas systems can potentially correct genetic mutations and edit epigenetic marks that contribute to respiratory disorders, providing a form of personalized medicine that could be used in conjunction with other technologies such as stem cell reprogramming and transplantation. CRISPR gene editing is a young field of research, and concerns regarding its specificity, as well as the need for efficient and safe delivery methods, need to be addressed further. However, CRISPR/Cas systems represent a significant step forward for research and therapy in respiratory health, and it is likely we will see the breakthroughs generated from this technology continue.",
keywords = "clustered regularly interspaced palindromic repeats-associated systems, gene editing, gene expression regulation, lung diseases, respiratory tract diseases, CYSTIC-FIBROSIS, TARGETING SPECIFICITY, GENE KNOCKOUT, MOUSE MODEL, HUMAN-CELLS, CAS9, DNA, CANCER, ENDONUCLEASE, NUCLEASES",
author = "Colette Moses and Parwinder Kaur",
year = "2019",
month = "7",
doi = "10.1111/resp.13527",
language = "English",
volume = "24",
pages = "628--637",
journal = "Asian Pacific Journal of Respirology",
issn = "1323-7799",
publisher = "John Wiley & Sons",
number = "7",

}

Applications of CRISPR systems in respiratory health : Entering a new 'red pen' era in genome editing. / Moses, Colette; Kaur, Parwinder.

In: Respirology, Vol. 24, No. 7, 07.2019, p. 628-637.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Applications of CRISPR systems in respiratory health

T2 - Entering a new 'red pen' era in genome editing

AU - Moses, Colette

AU - Kaur, Parwinder

PY - 2019/7

Y1 - 2019/7

N2 - Respiratory diseases, such as influenza infection, acute tracheal bronchitis, pneumonia, tuberculosis, chronic obstructive pulmonary disease, asthma, lung cancer and nasopharyngeal carcinoma, continue to significantly impact human health. Diseases of the lung and respiratory tract are influenced by environmental conditions and socio-economic factors; however, many of these serious respiratory disorders are also rooted in genetic or epigenetic causes. Clustered regularly interspaced palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins, isolated from the immune system of prokaryotes, provide a tool to manipulate gene sequences and gene expression with significant implications for respiratory research. CRISPR/Cas systems allow preclinical modelling of causal factors involved in many respiratory diseases, providing new insights into their underlying mechanisms. CRISPR can also be used to screen for genes involved in respiratory processes, development and pathology, identifying novel disease drivers or drug targets. Finally, CRISPR/Cas systems can potentially correct genetic mutations and edit epigenetic marks that contribute to respiratory disorders, providing a form of personalized medicine that could be used in conjunction with other technologies such as stem cell reprogramming and transplantation. CRISPR gene editing is a young field of research, and concerns regarding its specificity, as well as the need for efficient and safe delivery methods, need to be addressed further. However, CRISPR/Cas systems represent a significant step forward for research and therapy in respiratory health, and it is likely we will see the breakthroughs generated from this technology continue.

AB - Respiratory diseases, such as influenza infection, acute tracheal bronchitis, pneumonia, tuberculosis, chronic obstructive pulmonary disease, asthma, lung cancer and nasopharyngeal carcinoma, continue to significantly impact human health. Diseases of the lung and respiratory tract are influenced by environmental conditions and socio-economic factors; however, many of these serious respiratory disorders are also rooted in genetic or epigenetic causes. Clustered regularly interspaced palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins, isolated from the immune system of prokaryotes, provide a tool to manipulate gene sequences and gene expression with significant implications for respiratory research. CRISPR/Cas systems allow preclinical modelling of causal factors involved in many respiratory diseases, providing new insights into their underlying mechanisms. CRISPR can also be used to screen for genes involved in respiratory processes, development and pathology, identifying novel disease drivers or drug targets. Finally, CRISPR/Cas systems can potentially correct genetic mutations and edit epigenetic marks that contribute to respiratory disorders, providing a form of personalized medicine that could be used in conjunction with other technologies such as stem cell reprogramming and transplantation. CRISPR gene editing is a young field of research, and concerns regarding its specificity, as well as the need for efficient and safe delivery methods, need to be addressed further. However, CRISPR/Cas systems represent a significant step forward for research and therapy in respiratory health, and it is likely we will see the breakthroughs generated from this technology continue.

KW - clustered regularly interspaced palindromic repeats-associated systems

KW - gene editing

KW - gene expression regulation

KW - lung diseases

KW - respiratory tract diseases

KW - CYSTIC-FIBROSIS

KW - TARGETING SPECIFICITY

KW - GENE KNOCKOUT

KW - MOUSE MODEL

KW - HUMAN-CELLS

KW - CAS9

KW - DNA

KW - CANCER

KW - ENDONUCLEASE

KW - NUCLEASES

U2 - 10.1111/resp.13527

DO - 10.1111/resp.13527

M3 - Review article

VL - 24

SP - 628

EP - 637

JO - Asian Pacific Journal of Respirology

JF - Asian Pacific Journal of Respirology

SN - 1323-7799

IS - 7

ER -